Hormone News and Research

RSS

A hormone is a chemical released by one or more cells that affects cells in other parts of the organism. Only a small amount of hormone is required to alter cell metabolism. It is essentially a chemical messenger that transports a signal from one cell to another.

Novartis announces FDA approval of Signifor LAR for treatment of patients with acromegaly

Novartis announced today that the US Food and Drug Administration has approved Signifor long-acting release (LAR) (pasireotide) for injectable suspension, for intramuscular use, for the treatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option.

16 Dec 2014

Oncotype DX assay linked to decrease in chemotherapy use in younger patients

In what's believed to be one of the largest population-based studies of Oncotype DX ever conducted, researchers at The University of Texas MD Anderson Cancer Center have found that the commercial diagnostic tool, Oncotype DX, was associated with a decrease in chemotherapy use in younger patients, but not in those over 66 years of age.

14 Dec 2014

Pharmacyclics receives BayBio's 2014 Pantheon DiNA Award for Outstanding Company

Pharmacyclics, Inc. today announced that it has been awarded BayBio's 2014 Pantheon DiNA Award for Outstanding Company for its rapid development and commercialization of IMBRUVICA (ibrutinib). The award was presented at BayBio's 11th Annual Pantheon DiNA Awards ceremony in San Francisco.

13 Dec 2014

UB study creates new awareness for diabetics who are at risk for dehydration

Some drugs used to treat diabetes mimic the behavior of a hormone that a University at Buffalo psychologist has learned controls fluid intake in subjects. The finding creates new awareness for diabetics who, by the nature of their disease, are already at risk for dehydration.

12 Dec 2014

Three studies reveal effects of blocking androgen receptors in breast cancer

Three studies presented by University of Colorado Cancer Center researchers at the San Antonio Breast Cancer Symposium 2014 demonstrate the effects of blocking androgen receptors in breast cancer.

12 Dec 2014

Preventive effect of tamoxifen drug for breast cancer remains virtually constant for 20 years

The preventive effect of breast cancer drug 'tamoxifen' remains virtually constant for at least 20 years - with rates reduced by around 30 per cent - new analysis published in The Lancet Oncology reveals.

12 Dec 2014

CWRU researchers find mechanism that enables LRAT enzyme to store vitamin A

Researchers at Case Western Reserve University School of Medicine have uncovered the mechanism that enables the enzyme Lecithin: retinol acyltransferase (LRAT) to store vitamin A — a process that is indispensable for vision.

12 Dec 2014

Drugs delay disease progression for women with hormone-receptor-positive metastatic breast cancer

A new combination of cancer drugs delayed disease progression for patients with hormone-receptor-positive metastatic breast cancer, according to a multi-center phase II trial. The findings of the randomized study (S6-03) were presented at the 2014 San Antonio Breast Cancer Symposium, held Dec. 6-9, by Kerin Adelson, M.D., assistant professor of medical oncology at Yale Cancer Center and chief quality officer at Smilow Cancer Hospital at Yale-New Haven.

11 Dec 2014

New therapeutic approach for women with estrogen-receptor-positive breast cancer

Loyola researchers and collaborators have reported promising results from a novel therapeutic approach for women with estrogen-receptor-positive breast cancer.

11 Dec 2014

Male hormone testosterone may increase risk of colon cancer

Previous cancer research has revealed that women are less likely than men to suffer from non-sex specific cancers such as cancer of the colon, pancreas and stomach. Scientists theorized that perhaps this trend was due to a protecting effect created by female hormones, such as estrogen, that help prevent tumors from forming. Now, researchers at the University of Missouri have found evidence suggesting that the male hormone testosterone may actually be a contributing factor in the formation of colon cancer tumors.

11 Dec 2014

Enzymatic activity essential for vision may provide target for drug transport

10 Dec 2014

Novo Nordisk introduces new initiative to support healthy lifestyle programming in New Jersey area

Novo Nordisk today announced the launch of the Community Health Collaborative, a new initiative to support and expand healthy lifestyle programming in the Trenton, New Jersey area.

From Novo Nordisk 10 Dec 2014

Heat-shock protein 90 enables ER+ breast cancers to develop resistance to hormonal therapy

Long known for its ability to help organisms successfully adapt to environmentally stressful conditions, the highly conserved molecular chaperone heat-shock protein 90 (HSP90) also enables estrogen receptor-positive (ER+) breast cancers to develop resistance to hormonal therapy.

10 Dec 2014

$IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL$

IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL

New IMBRUVICA (ibrutinib) Phase II data announced by Pharmacyclics, Inc. today demonstrates its potential utility as a combination therapy when used with rituximab. Data suggest that the overall efficacy and safety profile of IMBRUVICA is well tolerated when combined with rituximab in patients with relapsed or refractory mantle cell lymphoma (MCL).

9 Dec 2014

Triple hormone reduces body weight, improves insulin sensitivity

Recently, the researchers had constructed several single molecules with dual hormone action. Now, for the first time, the researchers succeeded in designing a substance that combines three metabolically active hormone components (GLP-1, GIP and glucagon) and offers unmatched potency to fight metabolic diseases in pre-clinical trials.

9 Dec 2014

Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

Results from the Phase 2 RESONATE-17 (PCYC-1117) study show IMBRUVICA (ibrutinib) was associated with an 82.6 percent investigator-assessed overall response rate (ORR; the primary endpoint) and a 79 percent progression-free survival (PFS) rate at 12 months in people living with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have a genetic mutation known as deletion 17p (del 17p).

9 Dec 2014

McMaster University researchers identify hormone that contributes to obesity, diabetes

Researchers from McMaster University have identified an important hormone that is elevated in obese people and contributes to obesity and diabetes by inhibiting brown fat activity.

8 Dec 2014

Study highlights causes of postpartum disorders in new mothers

In the days shortly after giving birth, most mothers experience a period of increased calmness and decreased stress responses, but around 20% of mothers experience anxiety. Some women may become depressed, and around one in a thousand can develop psychosis. The latest evidence indicates that these distressing responses to motherhood are still poorly understood, but that animal research could provide valuable clues to their causes.

8 Dec 2014

Low doses of fluoxetine could hold key to preventing PMS symptoms

Low doses of fluoxetine - better known as the anti-depressant Prozac - could hold the key to preventing PMS symptoms, an international team of researchers has found.

8 Dec 2014

Most elderly women with early-stage breast cancer still receive radiation therapy despite less benefit

Women over the age of 70 who have certain early-stage breast cancers overwhelmingly receive radiation therapy despite published evidence that the treatment has limited benefit, researchers at Duke Medicine report.

8 Dec 2014

Hormone News and Research

Further Reading

Novartis announces FDA approval of Signifor LAR for treatment of patients with acromegaly

Oncotype DX assay linked to decrease in chemotherapy use in younger patients

Pharmacyclics receives BayBio's 2014 Pantheon DiNA Award for Outstanding Company

UB study creates new awareness for diabetics who are at risk for dehydration

Three studies reveal effects of blocking androgen receptors in breast cancer

Preventive effect of tamoxifen drug for breast cancer remains virtually constant for 20 years

CWRU researchers find mechanism that enables LRAT enzyme to store vitamin A

Drugs delay disease progression for women with hormone-receptor-positive metastatic breast cancer

New therapeutic approach for women with estrogen-receptor-positive breast cancer

Male hormone testosterone may increase risk of colon cancer

Enzymatic activity essential for vision may provide target for drug transport

Novo Nordisk introduces new initiative to support healthy lifestyle programming in New Jersey area

Heat-shock protein 90 enables ER+ breast cancers to develop resistance to hormonal therapy

IMBRUVICA-rituximab combination well tolerated in patients with relapsed or refractory MCL

Triple hormone reduces body weight, improves insulin sensitivity

Phase 2 RESONATE-17 study: IMBRUVICA (ibrutinib) improves survival in CLL patients with del 17p

McMaster University researchers identify hormone that contributes to obesity, diabetes

Study highlights causes of postpartum disorders in new mothers

Low doses of fluoxetine could hold key to preventing PMS symptoms

Most elderly women with early-stage breast cancer still receive radiation therapy despite less benefit

Viva Saliva Book: The ultimate guide to saliva Book preview Download eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News